The Lancet published results of a phase 2, randomized trial of TAK-875, a new treatment for type 2 diabetes online, which demonstrates that it is comparative to glimepiride in its ability to improve blood sugar control, but the risk of hypoglycemia, i.e. creating dangerous drops in blood sugar levels is substantially lower. Of the 150 million diabetics currently living in the U.S...
No comments:
Post a Comment